EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 842.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 476,250 shares of the company’s stock after buying an additional 425,717 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.89% of EyePoint Pharmaceuticals worth $4,143,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Ghisallo Capital Management LLC acquired a new stake in EyePoint Pharmaceuticals in the 4th quarter worth approximately $2,511,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter valued at $3,166,000. Ratan Capital Management LP acquired a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $1,040,000. Janney Montgomery Scott LLC boosted its position in EyePoint Pharmaceuticals by 26.5% in the first quarter. Janney Montgomery Scott LLC now owns 18,040 shares of the company’s stock valued at $373,000 after buying an additional 3,780 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of EyePoint Pharmaceuticals by 38.4% during the 1st quarter. American International Group Inc. now owns 18,378 shares of the company’s stock worth $380,000 after purchasing an additional 5,101 shares during the period. Institutional investors and hedge funds own 99.41% of the company’s stock.

Insider Activity

In related news, Director David R. Guyer sold 11,625 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $10.06, for a total transaction of $116,947.50. Following the transaction, the director now owns 1,850 shares in the company, valued at $18,611. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 4.74% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on EYPT shares. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, June 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a report on Thursday, June 20th. JPMorgan Chase & Co. dropped their price objective on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. One equities research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. According to data from MarketBeat, EyePoint Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $30.57.

EyePoint Pharmaceuticals Stock Down 1.1 %

EyePoint Pharmaceuticals stock opened at $7.98 on Friday. The company has a fifty day simple moving average of $8.70 and a 200-day simple moving average of $12.26. The firm has a market capitalization of $427.09 million, a price-to-earnings ratio of -4.38 and a beta of 1.59. EyePoint Pharmaceuticals, Inc. has a 52-week low of $5.67 and a 52-week high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. The business had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $11.61 million. On average, research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.